NICE ruling on prostate cancer drug questioned
Scientists have expressed their disappointment over a preliminary decision by the National Institute of Health and Care Excellence not to offer a life-extending drug to prostate cancer patients until after they have received chemotherapy.
You need to be a subscriber to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All HSJ news by sector, topic & region
- Breaking News announcements
- App for mobile and offline reading
- Comment and Daily Insights newsletters
- Regional roundup newsletters
- Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
- 10 expert briefings every fortnight (Premium only)
Already a subscriber? Sign into your account here